17.77
price down icon3.27%   -0.60
 
loading
前日終値:
$18.37
開ける:
$18.9
24時間の取引高:
1.86M
Relative Volume:
2.01
時価総額:
$1.22B
収益:
$161.10M
当期純損益:
$-308.60M
株価収益率:
-3.8051
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
-2.95%
1か月 パフォーマンス:
-4.31%
6か月 パフォーマンス:
-29.29%
1年 パフォーマンス:
-62.75%
1日の値動き範囲:
Value
$17.34
$19.05
1週間の範囲:
Value
$17.34
$20.38
52週間の値動き範囲:
Value
$16.61
$51.51

Arvinas Inc Stock (ARVN) Company Profile

Name
名前
Arvinas Inc
Name
セクター
Healthcare (1169)
Name
電話
203-535-1456
Name
住所
395 WINCHESTER AVE, NEW HAVEN, CT
Name
職員
430
Name
Twitter
@ArvinasInc
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
ARVN's Discussions on Twitter

ARVN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARVN
Arvinas Inc
17.77 1.22B 161.10M -308.60M -259.90M -4.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 開始されました BTIG Research Buy
2024-11-18 開始されました Stephens Overweight
2024-02-28 繰り返されました Oppenheimer Outperform
2024-02-14 ダウングレード Citigroup Buy → Neutral
2024-02-01 開始されました Goldman Buy
2023-12-19 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-06 アップグレード Jefferies Hold → Buy
2023-11-20 アップグレード Guggenheim Neutral → Buy
2023-10-23 アップグレード Wedbush Neutral → Outperform
2023-06-26 再開されました Oppenheimer Outperform
2023-01-12 ダウングレード Guggenheim Buy → Neutral
2023-01-03 ダウングレード Wells Fargo Overweight → Equal Weight
2022-09-09 開始されました Barclays Overweight
2022-06-21 開始されました Jefferies Hold
2022-05-09 ダウングレード Wedbush Outperform → Neutral
2022-04-28 開始されました Credit Suisse Outperform
2022-04-06 開始されました Morgan Stanley Equal-Weight
2022-02-11 再開されました BMO Capital Markets Outperform
2022-02-10 開始されました Wells Fargo Overweight
2022-01-19 開始されました Goldman Buy
2021-12-07 開始されました Cowen Outperform
2021-10-14 開始されました SVB Leerink Outperform
2021-09-30 開始されました Stifel Buy
2021-09-09 開始されました BofA Securities Buy
2021-05-21 開始されました UBS Buy
2021-04-21 開始されました Truist Buy
2021-03-31 開始されました BMO Capital Markets Outperform
2020-12-14 アップグレード Oppenheimer Perform → Outperform
2020-06-01 アップグレード Citigroup Neutral → Buy
2020-05-12 開始されました Oppenheimer Perform
2019-12-19 開始されました H.C. Wainwright Buy
2019-11-25 開始されました Guggenheim Buy
2019-10-24 アップグレード Goldman Neutral → Buy
2019-09-25 開始されました Wedbush Outperform
2019-09-12 開始されました BMO Capital Markets Outperform
2019-08-06 開始されました Cantor Fitzgerald Overweight
2019-06-05 ダウングレード Citigroup Buy → Neutral
2019-04-12 開始されました Evercore ISI Outperform
2018-10-22 開始されました Citigroup Buy
2018-10-22 開始されました Goldman Neutral
2018-10-22 開始されました Piper Jaffray Overweight
すべてを表示

Arvinas Inc (ARVN) 最新ニュース

pulisher
Feb 21, 2025

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Growth in Short Interest - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

Arvinas Operations describes new DGK-α inhibitors - BioWorld Online

Feb 20, 2025
pulisher
Feb 19, 2025

Equities Analysts Offer Predictions for Arvinas Q3 Earnings - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Arvinas (NASDAQ:ARVN) Trading 7.4% HigherHere's Why - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Wedbush Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

Earnings call transcript: Arvinas Q4 2024 surpasses EPS forecast, stock rises - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Oppenheimer Forecasts Strong Price Appreciation for Arvinas (NASDAQ:ARVN) Stock - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Arvinas (NASDAQ:ARVN) Receives Buy Rating from Guggenheim - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Analysts Offer Predictions for Arvinas FY2029 Earnings - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Arvinas (NASDAQ:ARVN) Stock Price Up 5% Following Better-Than-Expected Earnings - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

Arvinas (NASDAQ:ARVN) Given "Outperform" Rating at BMO Capital Markets - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Wedbush Reiterates Outperform Rating for Arvinas (NASDAQ:ARVN) - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

How the (ARVN) price action is used to our Advantage - Stock Traders Daily

Feb 15, 2025
pulisher
Feb 15, 2025

Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $0.44 EPS - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09% - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Arvinas Holding: Positive Earnings Call Highlights Growth - TipRanks

Feb 13, 2025
pulisher
Feb 13, 2025

Q1 Earnings Estimate for Arvinas Issued By Leerink Partnrs - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Call Transcript - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Arvinas Holding Faces Legal Risks Amid Stock Price Volatility - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

These Analysts Revise Their Forecasts On Arvinas After Q4 Results - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... By GuruFocus - Investing.com Canada

Feb 12, 2025
pulisher
Feb 12, 2025

Arvinas (ARVN) to Release Earnings on Tuesday - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... - Yahoo Finance

Feb 12, 2025
pulisher
Feb 11, 2025

Arvinas Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Arvinas Inc. (ARVN) reports earnings - Quartz

Feb 11, 2025
pulisher
Feb 11, 2025

ARVINAS, INC. SEC 10-K Report - TradingView

Feb 11, 2025
pulisher
Feb 11, 2025

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

Arvinas, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 11, 2025

Arvinas Inc (ARVN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Arvinas Inc (ARVN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Houston John G
President and CEO
Feb 23 '24
Sale
47.05
5,196
244,472
1,036,681
Cassidy Sean A
Chief Financial Officer
Feb 23 '24
Sale
47.05
1,702
80,079
181,916
Peck Ronald
Chief Medical Officer
Feb 23 '24
Sale
47.05
1,699
79,938
67,516
Taylor Ian
Chief Scientific Officer
Feb 23 '24
Sale
47.05
1,701
80,032
147,522
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):